6.3.6. treatment brain metastases. brain metastases occur context initial metastatic disease, systemic relapse rarely isolated site relapse. long-term survival patients presenting brain metastases diagnosis poor (30-50%) even poorer site recurrent disease (five-year survival-rate 2-5%) . large international database comprising 523 patients reported 48% three-year os rates patients brain metastases initial diagnosis 27% three-year os rates patients brain metastases relapse . chemotherapy initial treatment proved effective first-line setting (potentially even dose-intensified therapy upfront) data also supporting use multimodal treatment particularly relapsed disease . consolidation rt, even total response chemotherapy, therefore used patients brain metastases relapse, must carefully discussed first-line setting . surgery may considered cases persistent solitary metastasis, depending systemic disease status, histology primary tumour location metastasis. 6.3.6.1. summary evidence recommendations treatment metastatic testicular germ cell tumours summary evidencelein nsgct good-prognosis-risk group (igccg), bep x 3 superior chemotherapy regimens. toxicity lower treatment delivered five-day regimes rather three-day regimes.1bin nsgct intermediate-prognosis-risk group (igcccg) bep x 4 standard treatment choice five-year survival 89% contemporary series.1bin pathological stage ii nsgct disease, rplnd performed specialised centres without adjuvant chemotherapy results 73-81% long-lasting remissions.2bin patients poor-prognosis metastatic nsgct (defined igcccg), treatment bep x 4, results five-year pfs 67%. advantage os high-dose chemotherapy.1bpatients poor-prognosis metastatic nsgct early unfavourable tumour marker decline may benefit intensification treatment dose-dense chemotherapy, improvement pfs despite benefit observed os.1bfollowing first-line bep chemotherapy, 6-10% nsgct residual masses contain active cancer, 50% post-pubertal teratoma, 40% comprise necrotic-fibrotic tissue only. figures regarding persistence residual active slightly lower post chemotherapy residual masses < 1 cm. currently accurate prognostication method histology.2bin cs iia/b seminoma radiotherapy chemotherapy treatment show similar effectiveness, non-significant trend towards greater efficacy chemotherapy cs iib. however, risk second malignancies cardiovascular events higher radiotherapy.2ain metastatic seminoma stage > iic, primary chemotherapy bep, tailored igcccg risk group, proven superior carboplatin based chemotherapy.1bfluorodeoxyglucose-positron emission tomography high npv patients post-chemotherapy seminoma residual masses (> 3 cm) performed two months chemotherapy.2b recommendationsstrength ratingtreat low-volume non-seminomatous germ cell tumour (nsgct) stage iia/b elevated markers like metastatic good- intermediate-prognosis risk group igcccg three four cycles cisplatin, etoposide, bleomycin (bep).strongnerve-sparing retroperitoneal lymph node dissection performed experienced surgeon specialised centre recommended initial treatment clinical stage (cs) iia nsgct disease without elevated tumour markers.weakrepeat staging six weeks making final decision management considered patients small volume (cs iia < 2 cm) marker-negative nsgct.weaktreat metastatic nsgct (stage > iic) intermediate prognosis four cycles standard bep.strongtreat metastatic nsgct poor prognosis favourable marker decline four cycles bep.strongassess tumour marker decline one cycle standard chemotherapy metastatic nsgct poor-prognosis. unfavourable decline, consider chemotherapy intensification.weakperform surgical resection visible (> 1 cm longest diameter) residual masses chemotherapy nsgct serum levels tumour markers normal normalising.strongoffer cisplatin chemotherapy according igcccg prognosis groups, alternatively radiotherapy seminoma patients stage ii a/b and, inform patient potential long-term side effects treatment options.weaktreat seminoma stage iic higher, primary chemotherapy according igcccg classification (bep x 3 good-prognosis bep x 4 intermediate prognosis).strong